Amanote Research
Register
Sign In
Empagliflozin/Linagliptin Single-Tablet Combination: First-In-Class Treatment Option
International Journal of Clinical Practice
- United States
doi 10.1111/ijcp.12720
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Date
August 25, 2015
Authors
V. Woo
Publisher
Wiley
Related search
Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Empagliflozin and Metformin Combination Therapy in Type 2 Diabetes Mellitus
International Journal of Basic and Clinical Pharmacology
Repositioning of Hypoglycemic Drug Linagliptin for Cancer Treatment
Frontiers in Pharmacology
Pharmacology
Linagliptin: Farmacology, Efficacy and Safety in Type 2 Diabetes Treatment
Diabetology and Metabolic Syndrome
Internal Medicine
Endocrinology
Metabolism
Diabetes
Bioequivalence of a Darunavir/Cobicistat Fixed-Dose Combination Tablet Versus Single Agents and Food Effect in Healthy Volunteers
Antiviral Therapy
Infectious Diseases
Pharmacology
Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results From the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study
Metabolism: Clinical and Experimental
Endocrinology
Metabolism
Diabetes
Budget Impact of a New, First-In-Class Triple Fixed Dose Combination Therapy for COPD Patients
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Combination of Empagliflozin and Metformin Therapy: A Consideration of Its Place in Type 2 Diabetes Therapy
Clinical Medicine Insights: Endocrinology and Diabetes
Internal Medicine
Endocrinology
Metabolism
Diabetes
First-Class State Change in Plaid
ACM SIGPLAN Notices
Computer Science
